CLOs on the Move

XPERIX

www.xperix.io

 
With over 40 years of experience, XPERIX is disrupting traditional consulting for PLM, ALM, and CAE / Simulation. We assist companies to take advantage of new solutions for 10% - 50% improvement in product and process improvement.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.xperix.io
  • Parkdale Avenue
    Rochester, MI USA 48307
  • Phone: 248.247.0055

Executives

Name Title Contact Details

Similar Companies

Design Phase Inc

Design Phase Inc is a Waukegan, IL-based company in the Business Services sector.

Cash Flow Consultants Inc

Cash Flow Consultants Inc is a Bridgeview, IL-based company in the Business Services sector.

Talogy

We are Talogy. The talent management experts. We craft solutions that screen, select, develop, and engage talent worldwide. By uniting the leading psychologists, data scientists, developers, and HR consultants we bring the power of psychology and technology together so you can make the best data-driven people decisions. With more than 30 million assessments delivered each year in more than 50 languages, we help clients discover organizational brilliance.

Ful Circle

Ful Circle is a Denver, CO-based company in the Business Services sector.

enGene

At enGene, we are at the vanguard of a new era in genetic medicine: Our novel Dually Derivatized Oligochitosan® (DDX) gene delivery platform is designed to enable localized delivery of multiple gene cargos, including RNA and DNA, directly to mucosal tissues and other organs — potentially overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic diseases into the mainstream of clinical practice. Our breakthrough Dually Derivatized Oligochitosan® (DDX) platform opens possibilities for streamlining the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues. Our lead product candidate, EG-70 (detalimogene voraplasmid), is a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer (NMIBC), a disease with a significant patient burden, high clinical needs, and massive healthcare system economic impact. Based on its preliminary efficacy and safety profile and ease of administration by urologists, EG-70, which is currently in a pivotal trial, can potentially benefit patients across a wide variety of clinical settings. As enGeneers, we are boldly focused on patients needs. We are a team of passionate experts with extensive experience in drug development and commercialization across oncology, respiratory, and several other therapeutic areas. Nasdaq: ENGN